• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A型行为与中心性浆液性脉络膜视网膜病变

Type-A behavior and central serous chorioretinopathy.

作者信息

Yannuzzi L A

出版信息

Retina. 1987 Summer;7(2):111-31. doi: 10.1097/00006982-198700720-00009.

DOI:10.1097/00006982-198700720-00009
PMID:3306853
Abstract

A consecutive series of newly-diagnosed patients with central serous chorioretinopathy (CSC) was compared to two independent control groups chosen from the same patient population for the presence of a Type A behavioral pattern based on the Jenkins Activity Survey. The patients selected as matched controls had painless, reduced central vision and other chorioretinal diseases (Group I), or non-chorioretinal ocular conditions (Group II). The Type A behavior was significantly more frequent in study patients than in either Control Group I (X2 = 6.1 and P less than 0.025) or Control Group II patients (X2 = 17.7 and P less than 0.001). When both control groups were combined for comparison to the CSP patients, there was also a highly significant difference with regard to Type A behavior (X2 = 14.1 and P less than 0.001). A comparison of Control Group I with Control Group II revealed no significant difference in Type A behavior. Subfactor analysis of the Type A behavior pattern was also studied. The results of this clinical study were used in conjunction with experimental evidence linking catecholamines with CSP in developing a multifactorial etiologic hypothesis. The hypothesis suggests that the eyes as an organ system, and the macula as an ultimate target area, can be intermittently or continuously stimulated adversely by Type A behavior and its physiological consequences, most notably a sympathetic discharge. The multifactorial concept alludes to other potential risk factors such as age, race, sex, refractive state, or unknown tissue susceptabilities. The pathogenesis implies an inter-relationship between finely balanced components of a complex biopsychological system involving an individual's genetic endowment, his environment, and his behavioral pattern. The concept also offers new possible lines of investigation for the treatment of CSP, utilizing pharmacological regulators and for its prevention through early identification of CSP-prone individuals. A review of the pertinent cardiovasculature literature linking the Type A behavior with coronary artery disease and the significant papers in the ophthalmic literature on central serous pigment epitheliopathy are included in the discussion.

摘要

选取一系列新诊断的中心性浆液性脉络膜视网膜病变(CSC)患者,与从同一患者群体中选出的两个独立对照组进行比较,根据詹金斯活动调查来确定是否存在A型行为模式。选为匹配对照组的患者患有无痛性、中心视力下降以及其他脉络膜视网膜疾病(第一组),或非脉络膜视网膜眼部疾病(第二组)。研究患者中A型行为的发生率显著高于第一对照组(X2 = 6.1,P < 0.025)或第二对照组患者(X2 = 17.7,P < 0.001)。当将两个对照组合并与CSC患者进行比较时,在A型行为方面也存在高度显著差异(X2 = 14.1,P < 0.001)。第一对照组与第二对照组之间的A型行为比较未发现显著差异。还对A型行为模式的子因素进行了分析。这项临床研究的结果与将儿茶酚胺与CSC联系起来的实验证据相结合,以形成多因素病因假说。该假说认为,作为一个器官系统的眼睛以及作为最终目标区域的黄斑,可能会受到A型行为及其生理后果(最显著的是交感神经放电)的间歇性或持续性不良刺激。多因素概念还暗示了其他潜在风险因素,如年龄、种族、性别、屈光状态或未知的组织易感性。其发病机制意味着一个复杂的生物心理系统中精细平衡的成分之间存在相互关系,该系统涉及个体的遗传禀赋、环境和行为模式。这一概念还为CSC的治疗提供了新的可能研究方向,即利用药物调节剂,以及通过早期识别易患CSC的个体来进行预防。讨论中包括了将A型行为与冠状动脉疾病联系起来的相关心血管文献综述,以及眼科文献中关于中心性浆液性色素上皮病变的重要论文。

相似文献

1
Type-A behavior and central serous chorioretinopathy.A型行为与中心性浆液性脉络膜视网膜病变
Retina. 1987 Summer;7(2):111-31. doi: 10.1097/00006982-198700720-00009.
2
Type A behavior and central serous chorioretinopathy.A型行为与中心性浆液性脉络膜视网膜病变
Trans Am Ophthalmol Soc. 1986;84:799-845.
3
[Central serous chorioretinopathy and psychological stress].[中心性浆液性脉络膜视网膜病变与心理压力]
Ophthalmologe. 2000 Aug;97(8):527-31. doi: 10.1007/s003470070059.
4
[Central serous chorioretinopathy and systemic steroid therapy].[中心性浆液性脉络膜视网膜病变与全身类固醇治疗]
J Fr Ophtalmol. 2001 Feb;24(2):139-46.
5
Annular Lesions and Catenary Forms in Chronic Central Serous Chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变中的环形病变和悬链状形态
Am J Ophthalmol. 2016 Jun;166:60-67. doi: 10.1016/j.ajo.2016.03.025. Epub 2016 Mar 25.
6
Role of the tissue-type plasminogen activator -7351C > T and plasminogen activator inhibitor 1 4G/5G gene polymorphisms in central serous chorioretinopathy.组织型纤溶酶原激活剂-7351C>T和纤溶酶原激活剂抑制剂1 4G/5G基因多态性在中心性浆液性脉络膜视网膜病变中的作用。
Ophthalmic Genet. 2018 Dec;39(6):714-716. doi: 10.1080/13816810.2018.1536219. Epub 2018 Nov 15.
7
[Microperimetry evaluation in central serous chorioretinopathy].
Yan Ke Xue Bao. 2006 Sep;22(3):149-53.
8
Central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变
Optometry. 2008 May;79(5):241-51. doi: 10.1016/j.optm.2007.02.024.
9
[Central serous chorioretinopathy--clinical aspects and course].[中心性浆液性脉络膜视网膜病变——临床特征与病程]
Oftalmologia. 2006;50(3):123-7.
10
[Diffuse retinal epitheliopathy and central serous chorioretinopathy].[弥漫性视网膜上皮病变与中心性浆液性脉络膜视网膜病变]
J Fr Ophtalmol. 1983;6(4):339-49.

引用本文的文献

1
Interventions for central serous chorioretinopathy: a network meta-analysis.中心性浆液性脉络膜视网膜病变的干预措施:一项网状Meta分析
Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.
2
Central serous chorioretinopathy and autonomic dysfunction.中心性浆液性脉络膜视网膜病变与自主神经功能障碍。
Indian J Ophthalmol. 2025 Jun 1;73(6):930. doi: 10.4103/IJO.IJO_267_25. Epub 2025 May 28.
3
Anterior Segment Characteristics and Quality of Life of Patients with Central Serous Chorioretinopathy.中心性浆液性脉络膜视网膜病变患者的眼前节特征与生活质量
J Clin Med. 2025 Mar 7;14(6):1812. doi: 10.3390/jcm14061812.
4
Comparative efficacy of half-dose and one-third-dose photodynamic therapy in chronic central serous chorioretinopathy: a retrospective study.半剂量与三分之一剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的疗效比较:一项回顾性研究
Int J Retina Vitreous. 2025 Mar 18;11(1):32. doi: 10.1186/s40942-025-00657-6.
5
Sleep and mood in central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变中的睡眠与情绪
Eye (Lond). 2025 Jun;39(8):1615-1623. doi: 10.1038/s41433-025-03688-3. Epub 2025 Feb 26.
6
Resolution of subretinal fluid in intractable central serous chorioretinopathy with high-dose intravitreal aflibercept.高剂量玻璃体内注射阿柏西普治疗难治性中心性浆液性脉络膜视网膜病变时视网膜下液的消退
Am J Ophthalmol Case Rep. 2025 Jan 19;37:102266. doi: 10.1016/j.ajoc.2025.102266. eCollection 2025 Mar.
7
[Stress and other risk factors in central serous chorioretinopathy-A myth?].[中心性浆液性脉络膜视网膜病变中的压力及其他风险因素——一种误解?]
Ophthalmologie. 2025 Mar;122(3):162-169. doi: 10.1007/s00347-024-02179-2. Epub 2025 Jan 17.
8
Optical Coherence Tomography Study of Choroidal Response to Exercise-Induced Hypertension in Chronic Central Serous Chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变中脉络膜对运动诱发高血压反应的光学相干断层扫描研究
J Clin Med. 2024 Nov 1;13(21):6580. doi: 10.3390/jcm13216580.
9
Importance of OCT-derived biomarkers for the recurrence of central serous chorioretinopathy using statistics and predictive modelling.利用统计学和预测模型评估 OCT 衍生生物标志物在中心性浆液性脉络膜视网膜病变复发中的重要性。
Sci Rep. 2024 Oct 13;14(1):23940. doi: 10.1038/s41598-024-75275-7.
10
Pathogenesis of central serous choroidopathy: A novel hypothesis.中心性浆液性脉络膜病变的发病机制:一种新假说。
Indian J Ophthalmol. 2024 Oct 1;72(10):1387-1389. doi: 10.4103/IJO.IJO_2188_24. Epub 2024 Sep 27.